1 / 3

Randomized, double-blind active-control 10,462 high CV-risk hypertensive patients age 55+ yrs

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design. Randomized, double-blind active-control 10,462 high CV-risk hypertensive patients age 55+ yrs No history of symptomatic HF or evidence of LVEF<40%

hawa
Télécharger la présentation

Randomized, double-blind active-control 10,462 high CV-risk hypertensive patients age 55+ yrs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design • Randomized, double-blind active-control • 10,462 high CV-risk hypertensive patients age 55+ yrs • No history of symptomatic HF or evidence of LVEF<40% • Two fixed-dose antihypertensive combinations • HCTZ/benazepril (12.5-25/40 mg [ ACE force-titrated]) • Amlodipine/benazepril (5-10/40 mg [ACE force-titrated]) • Primary endpoint: CV mortality & morbidity • Morbidity: MI, stroke, hospitalized unstable angina, resuscitated sudden cardiac death, coronary revascularization • Mortality: sudden cardiac death, MI, stroke, coronary intervention, heart failure, other CV causes 8/20/2008 Jamerson KA et al., Am J Hypertens 2004;17:793-801

  2. ACCOMPLISH Preliminary Results:Primary* and Secondary End Points Jamerson KA, et al. March 31, 2008; Chicago, IL. http://www.theheart.org/article/852911.do 8/20/2008

  3. Perspective • May be promoted by some to encourage use of CCBs over thiazide-type diuretics (each with RAS inhibitors). • Calls for guidelines changes are premature. • Dose of thiazide-type diuretic – • Doses of thiazide-type diuretics equivalent to <25-50 mg/day HCTZ have not been evaluated in clinical outcome trials demonstrating the benefits of HCTZ on CVD outcomes • Data on HF not provided for ACCOMPLISH • In ALLHAT, adequate dosage of diuretic was superior to both the CCB and ACE-inhibitor in preventing HF and unsurpassed for other CVD-renal outcomes 8/20/2008

More Related